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Abstract
Background: Endothelial function has been shown to be a highly sensitive marker for the overall cardiovascular
risk of an individual. Furthermore, there is evidence of important sex differences in endothelial function that may
underlie the differential presentation of cardiovascular disease (CVD) in women relative to men. As such, measuring
endothelial function may have sex-specific prognostic value for the prediction of CVD events, thus improving risk
stratification for the overall prediction of CVD in both men and women. The primary objective of this study is to
assess the clinical utility of the forearm hyperaemic reactivity (FHR) test (a proxy measure of endothelial function)
for the prediction of CVD events in men vs. women using a novel, noninvasive nuclear medicine -based approach.
It is hypothesised that: 1) endothelial dysfunction will be a significant predictor of 5-year CVD events independent
of baseline stress test results, clinical, demographic, and psychological variables in both men and women; and 2)
endothelial dysfunction will be a better predictor of 5-year CVD events in women compared to men.
Methods/Design: A total of 1972 patients (812 men and 1160 women) undergoing a dipyridamole stress testing
were recruited. Medical history, CVD risk factors, health behaviours, psychological status, and gender identity were
assessed via structured interview or self-report questionnaires at baseline. In addition, FHR was assessed, as well as
levels of sex hormones via blood draw. Patients will be followed for 5 years to assess major CVD events (cardiac
mortality, non-fatal MI, revascularization procedures, and cerebrovascular events).
Discussion: This is the first study to determine the extent and nature of any sex differences in the ability of
endothelial function to predict CVD events. We believe the results of this study will provide data that will better
inform the choice of diagnostic tests in men and women and bring the quality of risk stratification in women on
par with that of men.
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Background
Endothelial function: a potentially novel predictor of
cardiovascular disease (CVD) risk in men and women
The endothelium is the largest endocrine organ in the
human body and is involved in the control of vascular
tone, platelet reactivity, coagulation, and permeability
[1]. As such, a healthy endothelium protects against
excessive/abnormal inflammation and coagulation [2],
which are key processes in CVD development and pro-
gression. The transition from a normal to a dysfunc-
tional endothelium is associated with abnormal
vasomotor activity, the development of a pro-coagulant
surface, and an acceleration of the inflammation process
[1]. As such, loss of normal endothelial function is a key
event in the initiation and progression of atherosclerosis
[3].
It has been suggested that the association between
endothelial dysfunction and classical risk factors for
atherosclerosis (e.g., age, diabetes, hypertension, smok-
ing, dyslipidemia) [4] supports the concept that
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grated risk of risk factors”, indicating that it could serve
as a highly sensitive marker for the overall cardiac risk
of an individual [5]. In addition, a recent review found
that patients with endothelial dysfunction had a 3.5
(range 2.5 - 5.0) greater chance of having a cardiac
event compared to those with normal endothelial func-
tion [4]. Taken together, these findings suggest that
measuring endothelial function has good prognostic
value for the prediction of CVD events, and may be
superior to more traditional methods of risk stratifica-
tion (e.g., Framingham Risk Score). This potential utility
is underscored by the fact that in many cases, traditional
methods for stratifying cardiac risk in individuals are
poor. For example, one study including over 12,000 men
and women from Scotland reported that the Framing-
ham Risk Score significantly underestimated cardiovas-
cular mortality [6]. In addition, both the Framingham
Risk Score and the National Cholesterol Education Pro-
gram (NCEP) model have been shown to generally
underestimate CVD risk in women [7-10]. Moreover,
the Framingham Risk Score has been shown to overesti-
mate CVD risk in men, particularly among non-Ameri-
can cohorts [11,12]. Similar limitations have been found
with other risk models (e.g., the Reynolds Risk Score)
[13,14]. As such, there is clearly a need for better pre-
diction tools that provide more reliable estimates in
men and women.
Sex differences in endothelial function
T h e r ei se v i d e n c eo fi m p o r t a n ts e xd i f f e r e n c e si n
endothelial function, many of which may underlie the
differential presentation of CVD in women relative to
men [15-17]. Women have greater microvascular dys-
function relative to men [18], which seems to be impor-
tant in the aetiology of endothelial dysfunction.
Moreover, both chest discomfort and chest pain in the
absence of overt coronary artery disease have been
linked to greater endothelial dysfunction in women [19].
There is also evidence of direct sex hormone effects on
endothelial function. For example, the menstrual cycle
has been shown to modulate endothelial function in
healthy women. Specifically, studies have indicated that
there is an increase in endothelium-dependent vasodila-
tion as women pass from the follicular phase to the
luteal phase [20,21], a period associated with an estro-
gen surge [21]. In comparison to healthy, age-matched
men, healthy women tend to have better endothelial
function, which may be due to improvements seen in
both the follicular and luteal phases (compared to
menses) [22]. However, it should be noted that another
study found that brachial artery endothelium-dependent
vasodilation (as measured by ultrasound) was better in
w o m e nc o m p a r e dt om e n ,b u tt h i sw a sl a r g e l y
dependant on basal brachial artery diameter rather than
hormonal effects [23].
Further evidence of a link between sex, endothelial
function, and CVD is highlighted by the fact that the
earlier onset of CVD in men relative to women mirrors
a similar pattern for endothelial function, with age-
related endothelial dysfunction also occurring earlier in
men than women [24,25]. However, around the time of
menopause, women have a steep decline in endothelial
function such that their endothelial deterioration rapidly
catches up with that of men [26,27]. Finally, estrogen,
progesterone, and androgen receptors have all been
found in abundance in human vascular endothelium,
with specific sex differences in the expression of hor-
mone receptors [28]. Not only does hormone replace-
ment therapy directly stimulate endothelial receptors,
but also indirectly modifies molecules known to affect
the endothelium, e.g., lipoproteins, homocysteine [29].
Though it has been suggested that endothelial func-
tion has good prognostic value for the prediction of a
broad range of important CVD events [4], to our knowl-
edge, no studies to date have specifically assessed sex
differences in the prognostic value of endothelial func-
tion testing. If there are sex-specific differences in the
processes underlying risk factor injury and atherosclero-
tic responses that are responsible for the unique presen-
tation of CVD in women, measuring endothelial
function may help elucidate these differences. It may
also help improve risk stratification and the overall pre-
diction of CVD in both men and women.
Current measures of endothelial function
There are currently no direct measures of endothelial
function. However, there are several indirect ways to
estimate endothelial function, most notably using inva-
sive coronary artery testing, the examination of blood
markers, and via non-invasive peripheral artery assess-
ments [30]. Due to their relative ease of administration,
i.e., use of non-invasive procedures, non-invasive arterial
methods are the most frequently used and include
plethysmography, ultrasound imaging, near infrared
spectrometry, and transcutaneous oximetry. Although
the optimal method of assessing endothelial function is
still under debate [31], ultrasound imaging of the bra-
chial artery during reactive hyperaemia (i.e., increased
blood flow) [32] is the most popular techniques. This
method, called flow-mediated dilatation, measures vas-
cular reactivity in response to hyperaemic challenge as
its proxy measure of endothelial function. Although it is
considered the current ‘gold standard,’ assessment of
flow mediated dilatation poses several important chal-
lenges. In order to have adequate within laboratory
reproducibility, administering this test requires very spe-
cialised training for the ultrasound technician, and even
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laboratory reliability [33]. These limitations have meant
that flow mediated dilatation has had limited clinical
utility [34]. The current study addresses these limita-
tions by employing a novel method of assessing brachial
artery reactivity (as a proxy measure of endothelial func-
tion) which has high reproducibility and reliability (see
below for details) [35].
Study Objectives, Aims and hypotheses
The primary objective of this study is to assess the
clinical utility of brachial artery reactivity (a proxy mea-
sure of endothelial function) for the prediction of CVD
events in men vs. women using a novel, noninvasive,
nuclear medicine-based approach based on the reactive
hyperemic response.
This study has the following specific aims:
Primary aim The primary aim is to prospectively evalu-
ate sex differences in the extent to which endothelial
function at baseline predicts risk for CVD events
(including cardiac mortality, non-fatal myocardial infarc-
tion (MI), percutaneous coronary intervention’s( P C I ’s),
coronary artery bypass graft surgery (CABG), and cere-
brovascular events) 5 years after a dipyridamole myocar-
dial perfusion imaging (MPI) test.
Hypotheses 1) Endothelial dysfunction (as measured by
brachial artery reactivity) will be a significant predictor
of CVD events independent of baseline stress test
results, clinical, demographic, and psychological vari-
ables in both men and women; and 2) endothelial dys-
function will be a better predictor of events at 5 years in
women compared to men.
Secondary aim To evaluate the prognostic value of
endothelial function testing compared to existing risk
measures (i.e., pharmacological (dipyridamole) testing
and the Framingham Risk Score) in men vs. women for
the prediction of CVD events.
Hypotheses 1) Endothelial function testing will demon-
strate greater sensitivity and specificity for the prediction
of CVD events at 5 years than the other risk measures;
2) Endothelial function testing will show greater sensi-
tivity and specificity for the prediction of CVD events at
5 years in women compared to men; and 3) Endothelial
function testing will add significant incremental prog-
nostic value to the other risk measures for the predic-
tion of CVD events.
Additional exploratory analyses will be conducted to
assess associations between various measures of psy-
chological stress (e.g., anxiety, depression) and health
behaviours (e.g., smoking, obesity, and physical activ-
ity) and endothelial function, and interactions between
these variables with sex/gender. This is based on evi-
dence suggesting that endothelial function may be
impacted by both psychological and behavioural fac-
tors, including depression, smoking, and obesity, and




A total of 1972 patients (812 men and 1160 women)
undergoing a dipyridamole stress single photon emission
computer tomography (SPECT) study in the Nuclear
Medicine Department of the Montreal Heart Institute
were recruited to undergo the baseline assessment.
Recruitment was carried out between January 2007 and
December 2010. As detailed in Figure 1, a total of 5822
patients presented to the department for dipyridamole
stress testing, of which 3383 (58%) were screened for
inclusion in the study. A total of 505 patients were
excluded. Of the remaining 2878 eligible patients, 475
(17%) refused to participate or did not show-up for their
appointment, 407 (14%) could not change their appoint-
ment to accommodate the testing schedule, and 24 (1%)


















• No staff = 421
• No FHR slots = 1185
• Technical prob. = 142
• No men = 403
• Missed = 300
Not eligible
• Other disease = 81
• Substance use = 0 
• Language = 347
• Cog. Limits = 32
• Other project = 45
Not recruited
• Refusal/no show = 475
• Technical diff. = 24
• No change appt. = 407
Figure 1 Baseline Study Recruitment. (TO APPEAR AT THE FOOT
OF THE TABLE) For those not approached, No staff = there were no
staff available for those patients; No FHR slots = all the slots were
taken for the days testing; Technical prob. = there were technical
problems with the SPECT camera’s and MPI testing was cancelled
for that time; No men = we were not recruiting men at certain
points to ensure an over sampling of women; Missed = the
research assistant was too busy with other participants to check
these dossiers.
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1972 patients, which was predominantly white (95%)
and for which the average (SD) age was 67 (10) years
for the men and 67 (10) years for the women. Based on
previous data collected by the investigators and use of
similar follow-up techniques [40], an approximate 15%
attrition rate is expected, which would result in a total
follow-up sample of around 1700 individuals.
Baseline Inclusion/Exclusion Criteria
To be included in the study, patients must have under-
gone an independent, medically-indicated (prescribed)
dipyridamole stress SPECT study, and be 18 years of
age or older. Patients were excluded if they (1) had a
serious co-morbid medical condition for which the
patient was not expected to survive the next 12 months
(e.g., chronic obstructive pulmonary disease, cancer,
other autoimmune disease); (2) smoked or consumed
caffeine or xanthine within 6 hours of the endothelial
function test; (3) were unable to speak English or
French; (4) had severe psychopathology (e.g., schizo-
phrenia), current substance abuse, or apparent cognitive
deficits (e.g., dementia) that would render the patient
unable to provide informed consent; (5) were currently
pregnant; or (6) they were participating in another study
which prohibited their involvement in the current study.
Study Design
Baseline
Patients were pre-screened to verify eligibility by a
trained clinical research assistant on the first day of a 2-
day SPECT study protocol when they presented to the
nuclear medicine department. On the day of their rest
perfusion image and following the injection of the
Tetrofosmin, eligible and consenting patients underwent
the forearm hyperemic reactivity (FHR) test (a nuclear
medicine based proxy measure of endothelial function,
see below) [35]. Sociodemographic, medical, clinical
(including menopause status and menstrual cycle phase
in women), and psychological data were collected across
the two days of the stress test protocol via structured
interview and self-report questionnaires. In addition, the
prevalence of depressive and anxiety disorders was
assessed using a brief structured psychiatric interview -
the Primary Care Evaluation of Mental Disorders
(PRIME-MD).
Follow-up
All patients will be re-contacted one, three, and five
years after enrolment to ascertain self-reported CVD
events and to determine changes in medical, beha-
vioural, and psychological status. These data will be col-
lected via questionnaire that will be mailed to
participants with a pre-addressed stamped envelope for
returning the information (see Figures 2 and 3 for the
follow-up algorithms). In addition, at the 5-year follow-
up assessment, patients will have the PRIME-MD re-
administered in person or by phone. All events occur-
ring over the 5-year follow-up will be confirmed (includ-
ing death) by reviewing hospital medical and provincial
electronic database (i.e., Régie de l’assurance maladie du
Québec [RAMQ], MedEcho, and the Institut de la statis-
tique du Québec [ISQ]) records. This study was
approved by the Research Ethics Board of the Montreal
Heart Institute and all patients provided written,
informed consent.






























* Patient will be called three times over a 1 week period at different times 
before family members will be contacted
Figure 2 Details of follow-up procedure for years 1 and 3.














obtain  contact 
details of 
patient
* Patient will be called three times
over a weeks period at different 
times before family members will 
be contacted
Figure 3 Details of the follow-up procedure for year 5.
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Dipyridamole stress test study
The dipyridamole test was carried out according to stan-
dard protocol [41]. The rest image was collected on day
1 and the dipyridamole stress image on day 2. For the
dipyridamole study, a total dose of .568 mg/kg of dipyri-
damole diluted in a 20 ml saline was infused at a regular
rate over a period of 4 min. A maximum dose of 50 mg
was used. A dose of 15 to 22 mCi of the radioactive tra-
cer (Technetium Tc-99 m Tetrofosmin) was injected 6
min after the administration of dipyridamole. Heart rate
was recorded by electrocardiogram (ECG: and electroni-
cally stored) at baseline, during every minute of the test,
and during recovery. Blood pressure was recorded every
1-3 min from baseline through to the end of recovery.
During recovery, aminophylline and/or nitroglycerine
was administered at the discretion of the attending phy-
sician. Approximately 45 min after the end of the test,
the patient had their SPECT image recorded. On the
rest day, the patient was injected with Technetium Tc-
99 m Tetrofosmin during the endothelial function test,
and had their SPECT image recorded approximately 45
min later.
SPECT images were obtained using a triple-head, large
field of view camera equipped with low-energy, high-
resolution, parallel-hole collimators. Sixty-four projec-
tions were acquired over a 360
o variable elliptic orbit on
a 64 × 64 × 16-byte matrix with a zoom of 1.44. A 20%
symmetric energy window centered on the 140 keV
peak was used. Processing will be performed using fil-
tered back-projection with a Butterworth filter (cutoff
0.7, order 8) without attenuation correction. Short-axis
slides, each one pixel thick (5.3 mm), will be recon-
structed and displayed as a two-dimensional polar map.
Standard software (Autoquant) estimates of stress, rest,
and stress-rest differential scores will be used to define
reversible stress-induced abnormal images (i.e.,
ischemia).
Assessment of endothelial function using the Forearm
Hypereamic Reactivity (FHR) test
Our technique for assessing endothelial function is a
nuclear medicine variation of the well-established flow-
mediated dilation protocol [35,42-44]. The approach is
based on the intravenous injection of a tracer and the
simultaneous non-invasive external detection of the tra-
cer ingress and transit into a forearm submitted to reac-
tive hyperaemia and the control contralateral forearm.
Approximately 1 hr before the rest SPECT image, a
hyperemic challenge was administered by the nuclear
technician by inflating a blood pressure cuff placed on
the right arm 50 mm Hg above systolic blood pressure
for 5 minutes. The patient was seated with both arms
extended over the top of large field of view gamma-
camera. Thirty seconds after sudden cuff release, the
Technetium Tc-99 m Tetrofosmin was injected as a
bolus. A dynamic (1 frame/second) image of the fore-
arms was recorded for 5 minutes. The standard SPECT
rest imaging was carried out approximately 30-45 min-
utes after the completion of testing. The specific mea-
sure of the FHR test which is used as a proxy of
endothelial function, the Rate of Uptake Ratio (RUR), is
derived by comparing the first-pass activity-time curves
between the hyperaemic and non-hyperaemic arms. In
our previous research, we found that an RUR of 3.55
discriminates between patients with and without coron-
ary artery disease (CAD), i.e., patients with a RUR ≤
3.55 were more likely to have CAD [35]. It is believed
t h a tah i g h e rR U Rm a yb ei n d i c a t i v eo fb e t t e re n d o t h e -
lial function (i.e., greater uptake in the hyperaemic arm
compared to the control arm). However, it should be
noted that whilst RUR is partly dependent on endothe-
lial function (as per flow-mediated dilatation), it is also
probable that there are other more global vascular fac-
tors which influence this too.
The FHR technique offers a number of advantages
over existing tests. It is a non-invasive technique that
allows for repeated measurements with an internal con-
trol (non-hyperaemic arm) and discriminates between
CAD and non-CAD patients with a high degree of sen-
sitivity (95%) and specificity (90%) [42]. It is easy to
administer and minimizes human error in administra-
tion of the test, is highly reproducible (intra-class r =
.89) [43], and shows high (r = .98) inter-rater reliability
[45]. In addition, it has the potential to be easily admi-
nistered in any centre with nuclear medicine facilities.
In contrast, the need for such facilities also limits its
wider usage in research and general medical settings (e.
g., primary care).
Demographic, Medical, and Health Behaviour Assessment
The following information was collected via structured
interview from each patient at baseline: age, ethnicity,
socioeconomic status (years of education, income, occu-
pation [46], and residential deprivation [47,48]), marital
status, current and lifetime history of CVD, CVD risk
factors [e.g., hypertension, hyperlipidemia], co-morbid
conditions, medications (including hormone replace-
ment therapy in women), details of immediate and
extended family history of CVD, levels of physical activ-
ity [49,50], and current and lifetime history of smoking
and alcohol use/abuse [51]. In addition, patients’ height,
weight, and waist circumference (WC) were measured
on the day of the stress test to calculate body mass
index (BMI) and central adiposity.
Psychiatric Disorders, psychological status, quality of life,
and gender identity
To assess depressive and anxiety disorders (which are
the most common psychiatric disorders seen in cardiac
populations) [52,53], patients underwent the mood and
Bacon et al. BMC Cardiovascular Disorders 2011, 11:50
http://www.biomedcentral.com/1471-2261/11/50
Page 5 of 9anxiety disorders modules of the Primary Care Evalua-
tion of Mental Disorders (PRIME-MD [54]). The
PRIME-MD is a brief, psychiatric interview that gener-
ates psychiatric diagnoses based on Diagnostic and Sta-
tistical Manual of Mental Disorders criteria. It takes 5-
15 minutes to administer and score, and yields diag-
noses of comparable sensitivity and specificity for indivi-
dual disorders (e.g., major depression: sensitivity (83%)
and specificity (88%) as longer structured interviews
[54]. Participants also completed a battery of self-report
psychological questionnaires including the Anxiety Sen-
sitivity Index [55], the Beck Anxiety Inventory [56], the
Beck Depression Inventory-II [57], the Whiteley Hypo-
chondriasis Scale [58], the Multidimensional Health
Locus of Control Scale [59], the Cook-Medley Hostility
I n v e n t o r y[ 6 0 ] ,a n dt h eS h o r tF o r m3 6q u a l i t yo fl i f e
scale [61]. Patients also completed the Bem Sex Role
Inventory [62] which measures gender identity (masculi-
nity and femininity).
Blood-Based Measures
On the day of the rest perfusion study and once the
catheter had been sited for the tracer injection, a blood
sample was drawn by the nuclear technician to obtain
biochemical measures. Fasting measures of C-reactive
protein, creatinine, uric acid, sedimentation, Haemoglo-
bin A1C, glucose, triglycerides, insulin, a lipid panel
(total cholesterol, high density lipoproteins, and low
density lipoproteins), and a full blood count were
obtained. In addition, we obtained measures of luteniz-
ing hormone (LH), follicular stimulating hormone
(FSH), estrogen, and testosterone in both men and
women.
Framingham Risk Score Calculation
The Framingham risk score will be determined for each
patient using medical and clinical data collected during
the baseline assessment. Separate risk scores for each
model will be calculated for men and women using the




At the end of the study (an average of 5 years post
recruitment of the baseline sample), all billable events
and diagnostic procedures occurring in the province of
Quebec will be obtained from the Commission de
l’accés à l’information du Québec (the Quebec access to
information commission). Patients and events will be
linked using a unique identifier (the numéro d’assurance
maladie: medical insurance number). Using the same
identifier, mortality data (including date and cause of
death) will be collected from the ISQ (Quebec’ss t a t i s t i c
institute). Using a standard protocol for the definition of
CVD events [64], the primary study endpoint will be
defined as a combination of cardiac mortality, non-fatal
MI, revascularization procedures, and cerebrovascular
events (i.e., stroke). In addition, self-reported informa-
tion regarding medical status and medications, as well
as all procedures and events undertaken since the last
follow-up contact will be collected.
Health behaviours
Information regarding changes in all health behaviours
assessed at baseline (e.g., tobacco and alcohol consump-
tion, physical activity level) will be collected. Self-
reported weight and WC will also be obtained to assess
changes in BMI and WC.
Psychological variables, quality of life, and gender role
To assess changes in psychological variables, patients
will complete the same self-report questionnaires as at
baseline. Also, at the final (5-year) assessment, patients
will undergo the PRIME-MD in person or by phone to
verify changes in psychiatric status.
Statistical Analyses
Primary aim
To test the main hypothesis, Cox proportional hazards
models will be used to evaluate the effect of sex and
endothelial function (independent binary variable,
defined using our previously published cut-point of 3.55
[35]) on the time of occurrence of composite CVD
events. Fixed covariates will be derived from baseline
stress test, clinical, demographic, and psychological
characteristics using Harrell’s guidelines [65]. The mod-
els will be validated for calibration and discrimination
using standard bootstrapping techniques [65]. In addi-
tion, we will estimate the concordance statistic (c-statis-
tic), which represents the probability that for a
randomly selected pair of individuals, one diseased and
one non-diseased, the diseased individual has the higher
estimated disease probability [66].
Secondary aims
To test the hypothesis that endothelial function will
have higher specificity and sensitivity than other risk
stratifiers (dipyridamole test and Framingham Risk
Score) in the prediction of CVD events, a series of recei-
ver operating characteristic (ROC) curve analyses will be
used, adjusting for covariates. Initially, ROC curve ana-
lyses will be conducted individually for endothelial func-
tion and the dipyridamole test or the Framingham Risk
Score, and the sensitivities and specificities will be com-
pared. Following this initial step, a final ROC curve will
be run where endothelial function and SPECT or the
Framingham Risk Score will be entered simultaneously,
which will allow for the determination of the additive
value of endothelial function. This data will allow us to
estimate both the positive and negative predictive value
of endothelial function. Three separate series of ROC
c u r v ea n a l y s e sw i l lb eu s e d ,o n ef o rm e n ,o n ef o r
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the extensive and varied number of tests, multiple tests
will be corrected with Benjamini and Hochberg’sF a l s e
Discovery Rate correction procedure [67-69]. All ana-
lyses will be conducted using SAS (SAS Inc, NC).
Power calculations
Power calculations were performed to detect significant
differences in the rate of CVD events identified in the
primary aim between women and men and between
those with normal RUR scores and those with reduced
RUR scores (i.e., endothelial dysfunction). According to
published data [70-72], we estimated an overall rate of
CVD events for women of 22% during the total follow-
up period. The equivalent estimate for men was 42%
[71,72]. Due to a dearth of data in women and a desire
to develop a solid database for future exploratory ana-
lyses, we decided to over sample women in the current
study, such that we would have 1200 (60%) women and
800 (40%) men. Given this sample size, combined event
rates over the course of the follow-up are expected to
be 30%. Adjustment of the sample size for an antici-
pated loss to follow-up of 15% would leave a final sam-
ple size of 1700 (1020 women and 680 men). In a
multivariate Cox regression analysis of the hazard ratio
(log) of CVD mortality on the predictor variable
‘endothelial dysfunction’ with an estimated SD of 0.48, a
0.05 significance level (two-sided), a variance inflation
factor of 0.2 for the sex interaction [73], and an R
2
adjustment of 0.5 for covariates, setting power at 0.9
would mean that a hazard ratio of 1.53 would be detect-
able. It should be noted that these estimates are conser-
vative and that a recent review of the effects of
endothelial function on CVD outcomes found that those
patients with endothelial dysfunction had about a 3.5
(range 2.5 - 5.0) greater likelihood of having a hard
CVD event compared to patients without [4]. It also
should be noted that as no previous study has assessed
the interaction of sex and endothelial function, this
more conservative estimate is an appropriate first strat-
egy. All sample size calculations were conducted using
the PASS system of NCSS [74].
Discussion
Limitations
Though the study has the potential to answer a number
of important clinical questions, there are several limita-
tions that should be noted. First, the selection of partici-
pants was not random and participants were
predominantly white. As such, the results may not gen-
eralise to all populations. Second, the recruitment of
patients undergoing dipyridamole stress tests implies
that this study population is a high risk one relative to
those undergoing standard exercise stress tests. As such,
the risk scores generated from the study may not be
used to generate risk estimates for individuals at low to
moderate risk of CVD. Third, the FHR test was con-
ducted using the resting SPECT isotope injection.
Whilst this has the benefit of reducing unnecessary
exposure to additional doses of radiation and lowers
cost, it does not allow us to test the independent (from
SPECT) application of the FHR test in a clinical setting.
It is anticipated that if the REWARD study provides
positive (prognostic) results, that future studies will
assess the cost-effectiveness of a stand-alone FHR test in
a clinical setting, noting the potential for greater radia-
tion exposure and potential patient safety concerns.
Originality, innovativeness, and importance
This is the first study to determine the extent and nat-
ure of any sex/gender differences in the ability of a
novel, nuclear-medicine based measure of endothelial
function to predict CVD events that holds great clinical
potential for use in cardiac risk stratification of men and
women. This is also the largest study to date to directly
compare the predictive ability of endothelial function
relative to existing risk models (e.g., dipyridamole test
and the Framingham Risk Score). We believe the results
of this study will provide data that will better inform the
choice of diagnostic tests in men and women and bring
the quality of risk stratification in women on par with
that of men.
List of Abbreviations
BMI: Body mass index; CABG: Coronary Artery Bypass Graft Surgery; CAD:
Coronary Artery Disease; CVD: Cardiovascular disease; FHR: Forearm
Hypereamic Reactivity; ISQ: Institut de la statistique du Québec; MI:
Myocardial Infarction; MPI: Myocardial Perfuction Imaging; NCEP: National
Cholesterol Education Program; PCI: Percutaneous Coronary Intervention;
PRIME-MD: Primary Care Evaluation of Mental Disorders; RAMQ: Régie de
l’assurance maladie du Québec; ROC: receiver operating characteristic; RUR:
Rate of Uptake Ratio; SPECT: Single photon emission computer tomography;
WC: Waist circumference.
Acknowledgements and Funding
The authors would like to acknowledge the following people for their help
in the collection and entry of the baseline data: Bernard Meloche, Lynn
Jolicoeur, Sandra Favret, Marie-Claude Poirier, Nadine Bekkouche, and Xueli
Zhao.
Funding for the collection of data was provided by two operating grants
from the Canadian Institutes of Health Research (MOP 79445 and MOP
89965). New investigator salary support was provided by the Fonds de la
recherche en santé du Québec (FRSQ) (KLL & SLB) and CIHR (SLB), and
student funding was provided by GENESIS (a CIHR ICE Team: CL), FRSQ (CL),
and the CIHR/Vanier scholarship program (JG).
Author details
1Montreal Behavioural Medicine Centre, Montreal, Canada.
2Research Centre,
Montreal Heart Institute - a University of Montreal affiliated hospital,
Montreal, Quebec, Canada.
3Department of Exercise Science, Concordia
University, Montreal, Quebec, Canada.
4Research Centre, Hôpital du Sacré-
Coeur de Montréal - a University of Montreal affiliated hospital, Quebec,
Canada.
5Department of Psychology, University of Quebec at Montreal
(UQAM), Montreal, Quebec, Canada.
6Department of Medicine, Université de
Montréal, Montreal, Quebec, Canada.
7Department of Medicine, McGill
Bacon et al. BMC Cardiovascular Disorders 2011, 11:50
http://www.biomedcentral.com/1471-2261/11/50
Page 7 of 9University, Montreal, Quebec, Canada.
8Department of Psychology, McGill
University, Montreal, Quebec, Canada.
Authors’ contributions
SLB and KLL conceived of the study, obtained funding for the study,
participated in its design and coordination, and drafted the manuscript. AA
carried out all FHR assessments and participated in the design of the study.
JD provided guidance on the outcomes assessments and participated in the
design of the study. LP participated in the design of the study, especially
around issues of gender and sex. CL coordinated the data collection and
provided input on the psychological measures included. JG participated in
data collection and provided input on the psychological measures included.
DG provided guidance on the statistical analyses and participated in the
design of the study. AV provided medical coverage for all baseline
assessments. All authors read and approved the final manuscript.
Competing interests
André Arsenault owns the patent rights for the FHR procedure (US
64,449,945 B1) and also owns 100% of SyGeSa Ltd who owns the rights for
the proprietary software used in the calculation of RUR.
The other authors declare that they have no competing interests.
Received: 4 March 2011 Accepted: 10 August 2011
Published: 10 August 2011
References
1. Quyyumi AA: Prognostic value of endothelial function. Am J Cardiol 2003,
91:19H-24H.
2. Healy B: Endothelial cell dysfunction: an emerging endocrinopathy
linked to coronary disease. J Am Coll Cardiol 1990, 16:357-358.
3. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G: Endothelial
Function Predicts Future Development of Coronary Artery Disease: A
Study of Women With Chest Pain and Normal Coronary Angiograms.
Circulation 2004, 109:2518-2523.
4. Lerman A, Zeiher AM: Endothelial function: cardiac events. Circulation
2005, 111:363-368.
5. Bonetti PO, Lerman LO, Lerman A: Endothelial Dysfunction: A Marker of
Atherosclerotic Risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
6. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC:
The accuracy of the Framingham risk-score in different socioeconomic
groups: a prospective study. British Journal of General Practice 2005,
55:838-845.
7. Akosah KO, Schaper A, Cogbill C, Schoenfeld P: Preventing myocardial
infarction in the young adult in the first place: how do the national
cholesterol education panel iii guidelines perform? J Am Coll Cardiol
2003, 41:1475.
8. Nasir K, Michos ED, Blumenthal RS, Raggi P: Detection of High-Risk Young
Adults and Women by Coronary Calcium and National Cholesterol
Education Program Panel III Guidelines. J Am Coll Cardiol 2005,
46:1931-1936.
9. Michos ED, Nasir K, Braunstein JB, Rumberger JA, Budoff MJ, Post WS,
Blumenthal RS: Framingham risk equation underestimates subclinical
atherosclerosis risk in asymptomatic women. Atherosclerosis 2006,
184:201-206.
10. Michos ED, Vasamreddy CR, Becker DM, Yanek LR, Moy TF, Fishman EK,
Becker LC, Blumenthal RS: Women with a low Framingham risk score and
a family history of premature coronary heart disease have a high
prevalence of subclinical coronary atherosclerosis. Am Heart J 2005,
150:1276-1281.
11. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S:
Predictive accuracy of the Framingham coronary risk score in British
men: prospective cohort study. Brit Med J 2003, 327:1267-1273.
12. Hense H-W, Schulte H, Lowel H, Assmann G, Keil U: Framingham risk
function overestimates risk of coronary heart disease in men and
women from Germany–results from the MONICA Augsburg and the
PROCAM cohorts. Euro Heart J 2003, 24:937-945.
13. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of
improved algorithms for the assessment of global cardiovascular risk in
women: The Reynolds Risk Score. Jounral of the American Medical
Association 2007, 297:611-619.
14. Blumenthal RS, Michos ED, Nasir K: Further improvements in CHD risk
prediction for women. JAMA 2007, 297:641-643.
15. Miller VM, Mulvagh SL: Sex steroids and endothelial function: translating
basic science to clinical practice. Trends Pharmacol Sci 2007, 28:263-270.
16. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M,
Matsubara J, Sumida H, Kaikita K, Kojima S, et al: Digital Assessment of
Endothelial Function and Ischemic Heart Disease in Women. J Am Coll
Cardiol 2010, 55:1688-1696.
17. Chow RWY, Handelsman DJ, Ng MKC: Minireview: Rapid Actions of Sex
Steroids in the Endothelium. Endocrinology 2010, 151:2411-2422.
18. Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Rogers WJ,
Reichek N, Rogers WJ, Bairey Merz CN, Sopko G, et al: Coronary
microvascular dysfunction is highly prevalent in women with chest pain
in the absence of coronary artery disease: results from the NHLBI WISE
study. Am Heart J 2001, 141:735-741.
19. Jacobs AK: Coronary Revascularization in Women in 2003: Sex Revisited.
Circulation 2003, 107:375-377.
20. Williams MR, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K,
Komesaroff PA: Variations in endothelial function and arterial compliance
during the menstrual cycle. J Clin Endocrinol Metab 2001, 86:5389-5395.
21. English JL, Jacobs LO, Green G, Andrews TC: Effect of the menstrual cycle
on endothelium-dependent vasodilation of the brachial artery in normal
young women. Am J Cardiol 1998, 82:256-258.
22. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y,
Taketani Y, Orimo H, Ouchi Y: Modulation of Endothelium-Dependent
Flow-Mediated Dilatation of the Brachial Artery by Sex and Menstrual
Cycle. Circulation 1995, 92:3431-3435.
23. Adams MR, Robinson J, Sorensen KE, Deanfield JE, Celermajer DS: Normal
ranges for brachial artery flow-mediated dilation: a non-invasive
ultrasound test of arterial endothelial function. Journal of Vascular
Investigation 1996, 2:146-150.
24. Zeiher AM, Drexler H, Saurbier B, Just H: Endothelium-mediated coronary
blood flow modulation in humans. Effects of age, atherosclerosis,
hypercholesterolemia, and hypertension. Journal of Clinical Investigation
1993, 92:652-662.
25. Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y,
Takeshita A: Effects of age on endothelium-dependent vasodilation of
resistance coronary artery by acetylcholine in humans. Circulation 1993,
88:77-81.
26. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D,
Robinson J, Deanfield JE: Aging is associated with endothelial dysfunction
in healthy men years before the age-related decline in women. JA m
Coll Cardiol 1994, 24:471-476.
27. Halligan SC, Murtagh B, Lennon RJ, Pumper GM, Mathew V, Higano ST,
Lerman A: Effect of Long-term Hormone Replacement Therapy on
Coronary Endothelial Function in Postmenopausal Women. Mayo Clin
Proc 2004, 79:1514-1520.
28. Sader MA, Celermajer DS: Endothelial function, vascular reactivity and
gender differences in the cardiovascular system. Cardiovasc Res 2002,
53:597-604.
29. Thompson J, Khalil RA: Gender differences in the regulation of vascular
tone. Clin Exp Pharm Physiol 2003, 30:1-15.
30. Farouque HMO, Meredith IT: The assessment of endothelial function in
humans. Coron Artery Dis 2001, 12:445-454.
31. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S,
Lerman A, Mancia G, Oliver JJ, Pessina AC, et al: Endothelial function and
dysfunction. Part I: Methodological issues for assessment in the different
vascular beds: A statement by the Working Group on Endothelin and
Endothelial Factors of the European Society of Hypertension. J Hypertens
2005, 23:7-17.
32. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI,
Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial
dysfunction in children and adults at risk of atherosclerosis. Lancet 1992,
340:1111-1115.
33. Sejda T, Pit’ha J, Svandova E, Poledne R: Limitations of non-invasive
endothelial function assessment by brachial artery flow-mediated
dilatation. Clinical Physiology and Functional Imaging 2005, 25:58-61.
34. Pyke KE, Tschakovsky ME: The relationship between shear stress and flow-
mediated dilatation: implications for the assessment of endothelial
function. Journal of Physiology 2005, 568:357-369.
Bacon et al. BMC Cardiovascular Disorders 2011, 11:50
http://www.biomedcentral.com/1471-2261/11/50
Page 8 of 935. Dupuis J, Arsenault A, Meloche B, Harel F, Staniloae C, Gregoire J:
Quantitative hyperemic reactivity in opposed limbs during myocardial
perfusion imaging: a new marker of coronary artery disease. J Am Coll
Cardiol 2004, 44:1473-1477.
36. Lavoie K, Pelletier R, Arsenault A, Dupuis J, Bacon S: Association Between
Clinical Depression and Endothelial Function Measured by Forearm
Hyperemic Reactivity. Psychosom Med 2010, 72:20-26.
37. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA:
Impaired Endothelial Function in Coronary Heart Disease Patients With
Depressive Symptomatology. J Am Coll Cardiol 2005, 46:656.
38. Michael Pittilo R: Cigarette smoking, endothelial injury and cardiovascular
disease. International Journal of Experimental Pathology 2000, 81:219-230.
39. Soodini GR, Hamdy O: Obesity and endothelial function. Current Opinion
in Endocrinology & Diabetes 2004, 11:186-191.
40. Jiang W, Babyak M, Krantz DS, Waugh RA, Coleman RE, Hanson MM,
Frid DJ, McNulty S, Morris JJ, O’Connor CM, Blumenthal JA: Mental stress–
induced myocardial ischemia and cardiac events. JAMA 1996,
275:1651-1656.
41. Strauss HW, Miller DD, Wittry MD, Cerqueira MD, Garcia EV, Iskandrian AS,
Schelbert HR, Wackers FJ, Balon HR, Lang O, Machac J: Procedure
Guideline for Myocardial Perfusion Imaging 3.3. Journal of Nuclear
Medicine Technology 2008, 36:155-161.
42. Arsenault A, Bacon SL, Lavoie KL, Meloche B: RUR and EWRU, new markers
of endothelial fucntion. Psychosom Med 2005, 67:A38.
43. Meloche B, Arsenault A, Lavoie KL, Bacon SL: Test-retest reliability of a
new method to measure endothelial function. Psychosom Med 2005, 67:
A54.
44. Dupuis J: Mechanisms of acute coronary syndromes and the potential
role of statins. Atherosclerosis 2001, 2:9-14.
45. Veldhuizen van Zanten J, Meloche B, Bacon SL, Stébenne PR, Arsenault A,
Lavoie KL: Inter-observer reliability of a new method to measure
endothelial function. Psychosom Med 2006, 68:A36.
46. Stevens G, Cho J: Socioeconomic indices and the new 1980 occupational
classification scheme. Social Science Research 1985, 14:142-168.
47. Pampalon R, Raymond G: A deprivation index for health and welfare
planning in Quebec. Chronic Diseases in Canada 2000, 21:104-113.
48. Taylor A, Cheng KK: Social deprivation and breast cancer. Journal of Public
Health Medicine 2003, 25:228-233.
49. Blair SN, Haskell WL, Ho P, Paffenbarger RS Jr, Vranizan KM, Farquhar JW,
Wood PD: Assessment of habitual physical activity by a seven-day recall
in a community survey and controlled experiments. Am J Epidemiol 1985,
122:794-804.
50. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN,
Paffenbarger RS Jr: Physical activity assessment methodology in the Five-
City Project. Am J Epidemiol 1985, 121:91-106.
51. Berkman L, Breslow L, Wingard D: Health practices and mortality risk. In
Health and ways of living: The Alameda County Study. Edited by: Berkman L,
Breslow L. New York: Academic Press; 1983:115-160.
52. Frasure-Smith N, Lesperance F: Reflections on depression as a cardiac risk
factor. Psychosom Med 2005, 67(Suppl 1):S19-25.
53. Roy-Byrne P, Davidson KW, Kessler RC, Asmundson GJ, goodwin RD,
Kubzansky L, Lydiard B, Massie MJ, Katon W, Laden SK, Stein MB: Anxiety
disorders and comorbid medical illness. General Hospital Psychiatry 2008,
30:208-225.
54. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR, Brody D,
Johnson JG: Utility of a new procedure for diagnosing mental disorders
in primary care. The PRIME-MD 1000 study. JAMA 1994, 272:1749-1756.
55. Reiss S, Peterson RA, Gursky DM, McNally RJ: Anxiety sensitivity, anxiety
frequency and the prediction of fearfulness. Behavioral Research Therapy
1986, 24:1-8.
56. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical
anxiety: psychometric properties. J Consult Clin Psychol 1988, 56:893-897.
57. Beck AT, Steer RA, Ball R, Ranieri W: Comparison of Beck Depression
Inventories -IA and -II in psychiatric outpatients. Journal of Personality
Assessment 1996, 67:588-597.
58. Pilowsky I: Dimensions of hypochondriasis. British Journal of Psychiatry
1967, 113:89-93.
59. Wallston KA, Stein MJ, Smith CA: Form C of the MHLC scales: a condition-
specific measure of locus of control. Journal of Personality Assessment
1994, 63:534-553.
60. Cook W, Medley D: Proposed hostility for Pharisaic-virtue skills of the
MMPI. Journal of Applied Psychology 1954, 38:414-418.
61. Jenkinson C, Coulter A, Wright L: Short form 36 (SF36) health survey
questionnaire: normative data for adults of working age. Brit Med J 1993,
306:1437-1440.
62. Bem SL: The measurement of psychological androgyny. J Consult Clin
Psychol 1974, 42:155-162.
63. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB:
Prediction of Coronary Heart Disease Using Risk Factor Categories.
Circulation 1998, 97:1837-1847.
64. Luepker RV, Evans A, McKeiguw P, Reddy KS: Cardiovascular survey methods.
3 edition. Geneva: World Health Organisation; 2004.
65. Harrell FE: Regression Modeling Strategies New York: Springer; 2001.
66. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996, 15:361-387.
67. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. J Royal Stat Soc 1995,
57:289-300.
68. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false
discovery rate in behavior genetics research. Behav Brain Res 2001,
125:279-284.
69. Benjamini Y, Yekutieli D: The control of the false discovery rate in
multiple testing under dependency. Annals of Statistics 2001,
29:1165-1188.
70. Johnson BD, Shaw LJ, Buchthal SD, Merz CNB, Kim HW, Scott KN, Doyle M,
Olson MB, Pepine CJ, den Hollander J, et al: Prognosis in women with
myocardial ischemia in the absence of obstructive coronary disease -
Results from the National Institutes of Health-National Heart, Lung, and
Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation
(WISE). Circulation 2004, 109:2993-2999.
71. Berman DS, Kang XP, Hayes SW, Friedman JD, Cohen I, Abidov A, Shaw LJ,
Amanullah AM, Germano G, Hachamovitch R: Adenosine myocardial
perfusion single-photon emission computed tomography in women
compared with men - Impact of diabetes mellitus on incremental
prognostic value and effect on patient management. J Am Coll Cardiol
2003, 41:1125-1133.
72. Heller GV, Herman SD, Travin MI, Baron JI, Santos-Ocampo C, McClellan JR:
Independent prognostic value of intravenous dipyridamole with
technetium-99 m sestamibi tomographic imaging in predicting cardiac
events and cardiac-related hospital admissions. J Am Coll Cardiol 1995,
26:1202-1208.
73. Hsieh FY, Lavori PW, Cohen H, Feussner JR: An overview of variance
inflation factors for sample-size calculation. Evaluation & The Health
Professions 2003, 26:239-257.
74. Hintze J: NCSS and PASS. 2004 [http://www.ncss.com].
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/11/50/prepub
doi:10.1186/1471-2261-11-50
Cite this article as: Bacon et al.: The research on endothelial function in
women and men at risk for cardiovascular disease (REWARD) study:
methodology. BMC Cardiovascular Disorders 2011 11:50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bacon et al. BMC Cardiovascular Disorders 2011, 11:50
http://www.biomedcentral.com/1471-2261/11/50
Page 9 of 9